Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder N/A Complete
Strensiq Asfotase alfa Hypophosphatasia, pediatric-onset List with criteria/condition Complete
Stribild Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate HIV infection List with criteria/condition Complete
Sublinox Zolpidem tartrate Insomnia Do not list Complete
Sublocade buprenorphine Opioid use disorder, treatment Reimburse with clinical criteria and/or conditions Complete
Suboxone Buprenorphine/naloxone Opioid drug dependence (Substitution treatment) List with clinical criteria and/or conditions Complete
Sunvepra Asunaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Sutent Sunitinib malate Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Sutent Sunitinib Gastrointestinal stromal tumour (GIST) List with clinical criteria and/or conditions Complete
Sutent Sunitinib malate Cancer, Metastatic renal cell carcinoma Do not list Complete